Can a smarter scan spot breast cancer treatment failure faster?

NCT ID NCT07130344

Not yet recruiting Knowledge-focused Sponsor: Centre Paul Strauss Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study compares two types of scans—standard CT and bone scans versus PET-CT—to see which better evaluates how well the drug trastuzumab deruxtecan (T-DXd) works in people with HER2 low metastatic breast cancer. About 262 participants will be split into two groups and scanned every 3 months. The goal is to find out if PET-CT can identify non-responders earlier, potentially avoiding unnecessary side effects and costs.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: trastuzumab deruxtecan (T-DXd)
What this could lead to: If successful, this could show that PET-CT scans detect treatment response earlier than standard CT scans, helping doctors avoid ineffective treatments sooner.
What could go wrong: This is an observational imaging study, not testing a new drug. The results may not change practice if PET-CT doesn't prove clearly better than standard scans.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER 2 LOW-EXPRESSING BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HER 2 LOW-EXPRESSING BREAST CANCER METASTATIC BREAST CANCER

Contacts and locations

Locations

ICANS

Strasbourg, 67033, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.